Search

Your search keyword '"Carcereny, E"' showing total 362 results

Search Constraints

Start Over You searched for: Author "Carcereny, E" Remove constraint Author: "Carcereny, E" Search Limiters Full Text Remove constraint Search Limiters: Full Text
362 results on '"Carcereny, E"'

Search Results

3. Avelumab in Combination With Lorlatinib or Crizotinib in Patients With Previously Treated Advanced NSCLC: Phase 1b/2 Results From the JAVELIN Lung 101 Trial

4. 3P Exploratory efficacy analysis by smoking status in PD-L1 high patients in the phase III, non-small cell lung cancer (NSCLC) IMpower110 study

5. P1.01-01 Frequency of Germline Mutations in Patients with Non-small Cell Lung Cancer (NSCLC) Harboring Actionable DRIVER Alterations (G-DRIVER)

7. P2.14-01 Patient-Reported Outcomes from IMfirst: Chemotherapy Plus Atezolizumab in a Real-World Setting of Extensive-Stage SCLC

8. MA03.11 Big Data and Artificial Intelligence for Exploring the Role of Genetic Risk. Family History of Cancer and Lung Cancer. Results from CLARIFY

9. P2.14-04 Treatment Beyond Progression with Atezolizumab in Extensive-Stage SCLC: Exploratory Analysis from the IMfirst Study

10. P1.21-04 Role of HLA-I as a Molecular Prognostic Factor for Long Term Responders in Non-small Cell Lung Cancer Patients Treated with Immunotherapy

11. P1.01-04 Clinical and Genetic Characteristics in Younger vs Older Lung Cancer Patients

12. P2.16-02 Pembrolizumab, Lenvatinib and Chemotherapy Combination in First Line Extensive-Stage Small Cell Lung Cancer: PEERS Phase 2 Trial

13. VP4-2023: Sotorasib 960 mg versus 240 mg in pretreated KRAS G12C advanced NSCLC

14. P2.17-06 Efficacy of Platinum after Lurbinectedin + DOX or Topotecan/CAV in Sensitive Relapsed SCLC Patients in the ATLANTIS Trial

15. EP11.03-13 Real-World Efficacy of Atezolizumab in Patients with Previously Treated Advanced NSCLC in Spain - TRACKER Study

18. Perioperative Pembrolizumab for Early-Stage Non-Small-Cell Lung Cancer

19. 107P Unveiling mismatch repair deficiency (dMMR) and microsatellite-instability high (MSI-H) detection in cancer patients (pt) using a next-generation sequencing (NGS)-based molecular pre-screening program (MPP)

20. P1.15-09 First-line Atezolizumab plus Bevacizumab for Metastatic High-Intermediate TMB in Non-squamous NSCLC. The TELMA Study.

22. P1.09-03 Multidisciplinary Thoracic Tumors Board Survey in Spain

23. OA06.04 Immune Response after SARS-CoV-2 Vaccination in Lung Cancer Patients. Update of the Covid Lung Vaccine Cohort

24. Two biomarker-directed randomized trials in European and Chinese patients with nonsmall-cell lung cancer: the BRCA1-RAP80 Expression Customization (BREC) studies

26. 39P Determination of essential biomarkers in lung cancer: A real-world data study in Spain

27. 32P Impact of smoking status on the relative efficacy of the EGFR TKI/angiogenesis inhibitor combination therapy in advanced NSCLC: A systematic review and meta-analysis

28. 38P The immunotherapy role in patients (pt) with KRAS mutated metastatic non-small cell lung cancer (NSCLC): Differences between KRAS G12C and non-G12C

30. Targeting KRAS in Lung Cancer Beyond KRAS G12C Inhibitors: The Immune Regulatory Role of KRAS and Novel Therapeutic Strategies

31. Representatividad del Registro de Tumores Torácicos de España. Comparación de datos sociodemográficos con otros registros nacionales

32. Biological and clinical perspectives of the actionable gene fusions and amplifications involving tyrosine kinase receptors in lung cancer

33. A randomised phase II study of osimertinib and bevacizumab versus osimertinib alone as second-line targeted treatment in advanced NSCLC with confirmed EGFR and acquired T790M mutations: the European Thoracic Oncology Platform (ETOP 10-16) BOOSTER trial

35. A randomised phase II study of osimertinib and bevacizumab versus osimertinib alone as second-line targeted treatment in advanced NSCLC with confirmed EGFR and acquired T790M mutations: the European Thoracic Oncology Platform (ETOP 10-16) BOOSTER trial

37. VP3-2021: A randomized phase II study of second-line osimertinib (Osi) and bevacizumab (Bev) versus Osi in advanced non-small-cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) and T790M mutations (mt): Results from the ETOP BOOSTER trial

38. OA14.01 Family History of Cancer and Lung Cancer: Information from the Thoracic Tumors Registry (TTR Study)

39. PL02.03 Lurbinectedin/Doxorubicin versus CAV or Topotecan in Relapsed SCLC Patients: Phase III Randomized ATLANTIS Trial

40. 1168P Clinical characteristics and survival in stage I-IIIA lung cancer resected patients in Spain, analyzed in the Thoracic Tumors Registry (TTR)

41. 1730P Cancer long survivor artificial intelligence follow-up (CLARIFY): Family history of cancer and lung cancer

43. 1272P First results of the early onset lung cancer (EOLUNG) study to characterize genomic alterations using FoundationOne CDx in young patients with non-small cell lung cancer

47. Head to head evaluation of second generation ALK inhibitors brigatinib and alectinib as first-line treatment for ALK+ NSCLC using an in silico systems biology-based approach

49. Small-Cell Lung Cancer Long-Term Survivor Patients: How to Find a Needle in a Haystack?

50. Lung Cancer Symptoms at Diagnosis: Data from the Thoracic Tumors Registry (TTR Study)

Catalog

Books, media, physical & digital resources